Skip to main content

Table 3 Attrition-weighted adjusted incidence rate ratios for benzodiazepine and anticholinergic medication use and incident dementia, stratified by cognition, sex and age

From: Anticholinergic and benzodiazepine medication use and risk of incident dementia: a UK cohort study

  Incidence rate ratio (95% confidence interval) by exposure
Subgroup Any Benzodiazepines Any ACB3 Any ACB12
MMSE at Y2 > 25 0.72 (0.35,1.50) 2.28 (1.32,3.92)* 0.99 (0.68,1.43)
MMSE at Y2 ≤ 25 1.23 (0.74,2.06) 0.94 (0.51,1.73) 0.78 (0.54,1.12)
Male 0.29 (0.06,1.31) 2.06 (0.78,5.46) 1.11 (0.66,1.89)
Female 1.17 (0.77,1.78) 1.24 (0.77,2.01) 0.85 (0.63,1.16)
Younger (born 1920–1929) 1.31 (0.52,3.27) 1.16 (0.45,3.01) 1.57 (0.82,3.00)
Older (born before 1920) 1.06 (0.69,1.61) 1.27 (0.78,2.09) 0.77 (0.58,1.03)
  1. *p < 0.01
  2. Abbreviations: MMSE Mini-Mental State Examination, ACB Anticholinergic Cognitive Burden, ACB12 use of a medicine with an ACB score of 1 or 2. Scores correspond to possibly anticholinergic (score 1), probably anticholinergic (score 2) and definitely anticholinergic (score 3). Number of observations and adjusted percentage in each group are reported in Additional file 3
\